Kidney Transplantation Recipients Clinical Trial
Official title:
First Tacrolimus Dose Trough Level is Better Than CYP3A5 Genotyping in Tacrolimus Dose Prediction
Tacrolimus dose highly varies among Asian kidney transplant recipients. This can be
explained by variety of CYP3A5 expression. CYP3A5 genotyping is highly recommended for
patients receiving tacrolimus. Here, we assessed the tacrolimus dose prediction by comparing
CYP3A5 expression and tacrolimus dosage using tacrolimus concentration after single dose
administration prior to kidney transplantation.
Plasma tacrolimus trough level was measured at 12 hours after first dose of 0.1 mg/kg of
tacrolimus (TacC12), orally administered in 51 new kidney transplant recipients. Patients
with CYP3A5 inhibitor/inducer co-medications were excluded. Genotyping for CYP3A5 expression
were carried out by RT-PCR. The dosages of tacrolimus at post-operative day 7 and dosage
which provided stable therapeutic levels in post-operative month 1 to 3 (C0 5-8 ng/mL) were
recorded.
The genotyping, TacC12, and target tacrolimus dosage have good correlations.
n/a
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01892761 -
MPA Pharmacokinetics in Renal Transplantation
|
N/A | |
| Completed |
NCT02025335 -
Assessment of CMV-specific ELISPOT Assay for Predicting CMV Infection in Kidney Transplant Recipients
|
N/A |